美国食品和药物管理局批准Arbli,一种新的薄荷味液体洛萨坦治疗高血压, FDA approves Arbli, a new peppermint-flavored liquid losartan for hypertension, marking a first in its form.

美国食品和药物管理局批准Arbli,Scienture Holdings的口服液态洛萨坦用于治疗高血压和相关疾病. The FDA has approved Arbli, Scienture Holdings' oral liquid losartan for treating hypertension and related conditions. 作为FDA首批批准的液态洛萨坦,Arbli为无法吞片的患者提供一种薄荷味的即用选择. As the first FDA-approved liquid losartan, Arbli offers a peppermint-flavored, ready-to-use option for patients who cannot swallow tablets. 预计10毫克/毫升制剂将于2025年第三季度启动。 The 10 mg/mL formulation is expected to launch in the third quarter of 2025. Scienture的股份在新闻上上升了约23.8%。 Scienture's shares rose by about 23.8% on the news.